Phosphoglucomutase1 is necessary for sustained cell growth under repetitive glucose depletion  by Bae, Eunju et al.
FEBS Letters 588 (2014) 3074–3080journal homepage: www.FEBSLetters .orgPhosphoglucomutase1 is necessary for sustained cell growth under
repetitive glucose depletionhttp://dx.doi.org/10.1016/j.febslet.2014.06.034
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
⇑ Corresponding authors. Fax: +82 2 312 5041.
E-mail addresses: KOHCHUN@yuhs.ac (E. Koh), KYUNGSUP59@yuhs.ac (K.-S. Kim).Eunju Bae, Hee Eun Kim, Eunjin Koh ⇑, Kyung-Sup Kim ⇑
Department of Biochemistry and Molecular Biology, Brain Korea 21 PLUS Project for Medical Sciences, Institute of Genetic Science, Integrated Genomic
Research Center for Metabolic Regulation, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
a r t i c l e i n f o a b s t r a c tArticle history:
Received 20 March 2014
Revised 9 June 2014
Accepted 10 June 2014
Available online 18 June 2014
Edited by Judit Ovádi
Keywords:
Phosphoglucomutase
Glycogen
Glycogenolysis
Glycogenesis
Nutritional stressPhosphoglucomutase (PGM)1 catalyzes the reversible conversion reaction between glucose-1-phos-
phate (G-1-P) and glucose-6-phosphate (G-6-P). Although both G-1-P and G-6-P are important inter-
mediates for glucose and glycogen metabolism, the biological roles and regulatory mechanisms of
PGM1 are largely unknown. In this study we found that T553 is obligatory for PGM1 stability and
the last C-terminal residue, T562, is critical for its activity. Interestingly, depletion of PGM1 was asso-
ciated with declined cellular glycogen content and decreased rates of glycogenolysis and glycogen-
esis. Furthermore, PGM1 depletion suppressed cell proliferation under long-term repetitive glucose
depletion. Our results suggest that PGM1 is required for sustained cell growth during nutritional
changes, probably through regulating the balance of G-1-P and G-6-P in order to satisfy the cellular
demands during nutritional stress.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cancer cells often encounter metabolic stresses such as glucose
depletion or hypoxia and have to use alternative metabolic path-
ways for survival and proliferation. Many enzymes involved in
glycolysis have been studied in the context of metabolic repro-
gramming of cancer cells [1–3].
Phosphoglucomutase 1 (PGM1; EC 5.4.2.2) catalyzes the revers-
ible conversion between glucose-1-phosphate (G-1-P) and
glucose-6-phosphate (G-6-P) via the intermediate glucose-1,6-bis-
phosphate (G-1,6-BP) in the presence of Mg2+ [4,5]. PGM1, which
belongs to the phosphohexose mutase family, account for
85–95% of the total PGM activity, and other isoforms, such as
PGM2 and PGM3, are for remainder of PGM activity in most tissues
even though PGM2 mainly functions as phosphopentose mutase
[6–8]. PGM1 has two major isoforms from alternatively spliced
ﬁrst exons with distinct tissue distributions [8]. There are several
reports demonstrated that defects in PGM1 caused abnormal glyco-
gen accumulation, impaired N-glycosylation and muscle symp-
toms such as exercise intolerance and rhabdomyolysis [9–11].
Although the classic enzymology of PGM1 has been extensively
studied, there are limited studies on the enzymatic regulation ofPGM1. Previous studies have shown that phosphorylated serine
108 of PGM1 acts as a phosphoryl group donor to produce
G-1,6-BP [5], that glycosylation of PGM in yeast appears to affect
its distribution [12], and that p21-activated kinase1 (Pak1) phos-
phorylates threonine 466 of PGM1 and enhances its enzymatic
activity [13].
As a substrate and/or a product of PGM1, G-1-P is an important
intermediate in glycogen, galactose, glycoprotein, and glycolipid
metabolism, therefore involved in various cellular functions
[14–16]. Likewise, G-6-P acts as a fundamental metabolic interme-
diate for glycolysis as well as the pentose phosphate pathway to
provide precursors for anabolic pathways and cofactors required
for cell proliferation [17]. Therefore, it is conceivable that PGM1
plays a critical role in cellular functions including cell survival
and proliferation by maintaining intracellular levels of G-1-P and
G-6-P through their rapid interconversion, thus contributing to
metabolic carbohydrate homeostasis.
Recently, considerable attention has been paid to the role of gly-
cogen metabolism in cancer cell survival and growth under hyp-
oxic and/or glucose depleted conditions [18–21]. Although PGM1
appears to be associated with hypoxia-induced accumulation of
glycogen in cancer cells [18], the physiological role of PGM1 in can-
cer cell survival and proliferation under conditions of nutrient
stress is largely unknown.
In this study we present evidence supporting a new regulatory
mechanism of PGM1 stability and activity that is attributed to
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knockdown cells exhibit signiﬁcantly diminished cell proliferation
under repeated exposure to a limited glucose supply. We propose
that PGM1 plays a role in metabolic adaptation against detrimental
nutritional status by rapid interconversion of G-1-P and G-6-P,
leading to persistent cell proliferation.2. Materials and methods
2.1. Cell culture and reagents
HEK 293T, MCF-7 and Hela cells were obtained from the ATCC
(Manassas, VA, USA) and cultured in DMEM containing 10% FBS
at 37 C under 5% CO2.
2.2. Plasmids and transfections
Human PGM1 cDNA (isoform1, NM_002633) was cloned into
pSG5-KHA2M1 for HA-tag at N-terminus, pET-21a and pQE for
6His tag at C-terminus and N-terminus, respectively. pLKO
shRNA plasmids targeting all three PGM1 isoforms were purchased
from Sigma–Aldrich. For transient transfection, Lipofectamine™
Reagent (Invitrogen) was used.
2.3. Western blot analysis
Cultured cells were harvested in lysis buffer (0.5% NP-40,
150 mM NaCl, 50 mM Tris–HCl, pH 7.4, 20 mM b-glycerophos-
phate, 1 mM Na3VO4, 10 mM NaF) containing a protease inhibitor
cocktail (Roche). Protein concentrations were determined by Brad-
ford assay [22] or bicinconinic acid (BCA) assay [23].
2.4. Recombinant protein expression
pQE30-PGM1 and pET21a-PGM1 was transformed into Rosset-
ta2 pLacI strain and BL21 (DE3) pLysS strain, respectively. Soluble
recombinant proteins were puriﬁed using Ni–NTA agarose
(Qiagen).
2.5. Phosphoglucomutase (PGM) activity assay
Measurement of G-6-P coupled with the G-6-P dehydrogenase
was used for the activity assay [24].
2.6. Glycogen quantiﬁcation
Glycogen was quantiﬁed using a starch assay kit (Sigma–
Aldrich) according to the manufacturer’s instructions.Fig. 1. Loss of PGM activity in PGM1 with C-terminal 6His tag. (A) Bacterial recomb
Measurement of PGM activity without 20 lM G-1,6-BP (B) or with G-1,6-BP in the en
independent experiments conducted in triplicate.2.7. Quantiﬁcation of G-1-P and G-6-P
G-1-P and G-6-P was quantiﬁed by slight modiﬁcation of ﬂuori-
metric assay [25].
2.8. Cell proliferation assay
Cells were plated in a 12-well plate (1  104 cells/well) and
exposed to intermittent 4-h pulses of 10 mM glucose between
20-h periods of glucose depletion. Cell numbers were counted
every 24 h for 4 days using ADAM-MC (NANOENTEK, South Korea).
2.9. Statistical analysis
All results are expressed as the mean ± S.D. of at least three
independent experiments.
Detailed materials and methods are included in the Supplemen-
tary materials.
3. Results
3.1. Intact C-terminus of PGM1 is critical for its enzymatic activity
To assess the enzymatic activity of PGM we used bacterial puri-
ﬁed recombinant PGM1 proteins containing six histidine tags
(6His) at the N- or C-terminus (Fig. 1A). As shown in Fig. 1B,
N-terminus 6His tagged PGM1 (6His-PGM1) had PGM enzy-
matic activity, whereas PGM1 with a C-terminus 6His tag
(PGM1-6His) completely lost activity. Addition of a potent activa-
tor of PGM1, G-1,6-BP, to the enzyme reaction mixture markedly
increased activity of 6His-PGM1 as expected, but no enhance-
ment was observed with PGM1-6His (Fig. 1C). These results
imply that an intact C-terminal region of PGM1 is critical for enzy-
matic function.
3.2. Characterization of the functional signiﬁcances of PGM1
C-terminal threonine residues
The C-terminal domain of the functionally similar enzyme
phosphoglycerate mutase (PGAM), which catalyzes the conversion
of 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG) through
2,3-bisphosphoglycerate (BPG) as an intermediate, is known to
affect catalytic efﬁciency [26–28]. Based on our observation that
addition of C-terminal 6His tags to PGM1 totally compromised
its enzymatic activity (Fig. 1), we assumed that the C-terminus of
PGM1 similarly contains critical residues that play a regulatory
role in enzymatic activity.
The C-terminus of PGM1 contains repeated threonine residues,
TXXTXXTXXT, that are highly conserved among different speciesinant PGM1 constructs containing 6His tags localized at the C- or N-terminus.
zyme assay reaction mixture (C). The results are representative of at least three
Fig. 2. Functional signiﬁcances of PGM1 C-terminal threonine residues. (A) Alignment of the C-terminal sequences of PGM1 showing conserved threonine residues. (B) Wild
type and threonine mutants of PGM1 constructs, pSG5-KHA2M1-hPGM1, which have N-terminus HA tag, were transiently expressed and whole cell lysates of HEK293T cells
were used for Western blot analysis. # indicates endogenous PGM1 protein expression. Green ﬂuorescence protein (GFP) expression vector was co-transfected to evaluate
transfection efﬁciency. Each plasmid was transfected in triplicate. Dividing lines on blot data indicate non-adjacent lanes of the same blot. (C) Recombinant PGM1 proteins of
wild type, T553E and T553A mutants. Lysates of E. coli expressing recombinant proteins were fractionated into soluble supernatant (S) and pellet (P) by centrifugation and
subjected to SDS–PAGE. Two separate colonies were tested for T553E and T553A mutants (#1 and #2). M: protein marker (D) PGM activity assay using HEK293T cell lysate.
PGM1 activity of mock was measured and the activity of each mutant was obtained by subtraction of mock activity from measured value of each sample (E) PGM activity by
measuring the conversion of G-1-P to G-6-P with afﬁnity column puriﬁed recombinant PGM1 proteins in the presence or absence of 20 lM G-1,6-BP. (F) Reverse PGM1
activity by measuring the conversion of G-6-P to G-1-P with puriﬁed recombinant PGM1 proteins in the presence of G-1,6-BP. (G) PGM activity was assayed with puriﬁed
recombinant PGM1 proteins (100 ng of WT and 200 ng of T562A) in the presence of indicated concentrations of G-1,6-BP. The results are representative of at least three
separate experiments conducted in triplicate. A unit of activity was deﬁned as the amount of enzyme required for the formation of 1 lmol of G-6-P per minute.
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modiﬁed by phosphorylation, we individually replaced each threo-
nine residue with glutamic acid (E) or alanine (A) to analyze its
functional consequences.
To assay the enzymatic activity of the mutated PGM1, each
mutant was expressed along with GFP in HEK293T cells (Fig. 2B).
Exogenous PGM1 migrated slower than endogenous PGM1 dueto 2HA tag at N-terminus. The expression level of exogenous wild
type PGM1 was much higher than that of endogenous enzyme.
However, expression of T553 mutants, particularly T553E, were
signiﬁcantly reduced relative to wild type protein (Fig. 2B). No dif-
ferences in GFP expression indicate that the altered expression of
the mutants were not due to transfection efﬁciency. To further
assess the role of T553 in protein expression, we attempted to
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niﬁcant proportion of wild type recombinant PGM1 was soluble
form. However, T553E mutant protein was mostly expressed as
insoluble aggregates forming inclusion bodies. Likewise, the
T553A mutation suppressed expression of the soluble form com-
pared with wild type. These results suggest that T553 is a critical
residue for folding of PGM protein into the correct conformation.
Notably, mutation (T562E, and T562A) or deletion of T562
(DT562) markedly attenuated PGM activity whereas mutation of
T556 and T559 did not affect activity (Fig. 2D). Wild type and all
of these mutants were efﬁciently expressed almost same levels
in HEK293T cells (Fig. S1A). In particular, T562E and DT562 muta-
tions almost completely abolished enzyme activity even in the
presence of G-1,6-BP. It is also notable that the severely repressed
activity of the T562A mutant was rescued by the addition of G-1,
6-BP. To exclude the effects of contaminants in HEK293T whole cell
lysates, bacterial soluble recombinant PGM1 proteins were homo-
geneously puriﬁed and their speciﬁc activities in both directions,
conversion of G-1-P to G-6-P and vice versa, were measured
(Figs. 2E,F and S1B). Consistent with the results from HEK293 cells,
mutation of T556 and T559 did not signiﬁcantly affect PGM enzy-
matic activity. In marked contrast, the T562E mutant completely
lost PGM activity even in the presence of G-1,6-BP. T562A mutant
protein also showed severely decreased activity but the addition of
G-1,6-BP induced its activity in much higher folds than wild type
enzyme (Fig. 2E). To precisely examine the response to G-1,6-BP
in T562A mutant, we investigated the effect of concentrations of
G-1,6-BP on PGM activity of T562A mutant. Activity of the T562A
mutant was linearly elevated according to the increased concentra-
tions of G-1,6-BP up to 20 nM, and further increased up to 100 nM,
whereas the activity of wild type PGM1 was saturated below 5 nM
G-1,6-BP (Fig. 2G). These results indicate that the T562A mutation
might destabilize the interaction with intermediary product,Fig. 3. PGM1 affects cellular glycogen content and its turnover rates. (A) MCF7 stable
(shNC) were assessed for PGM1 protein levels by Western blotting. GAPDH was used as
measured and expressed as ng/lg protein. (C) Rate of glycogenolysis was measured upon
24 h, washed with PBS, and incubated in medium containing no glucose. Intracellular gl
was measured upon 10 mM glucose replenishment after 24 h of glucose depletion. TheG-1,6-BP, resulting in dephospho-PGM1 inactive form. Taken
together, our data suggest that the T562 residue is critically
required for efﬁcient catalytic reaction of PGM1.
3.3. PGM1 affects glycogen metabolism in cancer cells under
conditions of glucose depletion
Recent studies have suggested a critical role of glycogen in can-
cer cell survival and proliferation [18–21]. Although PGM1 acts as a
gatekeeper in the metabolic pathway between glycogen and glu-
cose by catalyzing the interconversion of G-1-P and G-6-P, there
are few studies focusing on PGM1 function with respect to glyco-
gen content. On the basis of a recent report showing that induction
of glycogen storage and PGM1 expression are simultaneously
occurred under hypoxic conditions [18], we investigated the direct
effects of PGM1 on the cellular levels of glycogen.
To deﬁne a possible role of PGM1 in cellular glycogen metabo-
lism, we performed knockdown of PGM1 in MCF7 cells and quanti-
ﬁed the glycogen content. Compared with cells expressing negative
control shRNA (shNC), PGM1 knockdown cells (shPGM1) had lower
glycogen in high-glucose medium with no signiﬁcant difference in
glucose uptake (Figs. 3A,B and S2). However, the overexpression of
wild type PGM1 or catalytically defective T562E mutant failed to
increase the glycogen content indicating that the endogenous
PGM1 seems to be enough to reach the equilibrium state of glyco-
gen level (Fig. S3). Moreover, the rate of glycogenolysis induced by
glucose deprivation was markedly decreased in shPGM1 cells com-
pared with shNC cells, even though cellular glycogen was almost
completely depleted within 24 h after glucose starvation in both
cell lines with no changes in PGM1 expression level in control cells
(Figs. 3C and S4). In control shNC cells, the glycogen repletion was
almost completed within 2 h after replenishment of glucose due to
high rate of glycogen synthesis, whereas PGM1 knockdowncells infected with lentivirus expressing shRNA PGM1 (shPGM1) or control shRNA
an internal control. (B) Glycogen content in cells cultured at 25 mM glucose were
glucose deprivation. Cells were cultured in 25 mM glucose containing medium for
ycogen levels were measured at the indicated times. (D) Rate of glycogen synthesis
average and S.D. of triplicates were represented.
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cogen storage after glucose replenishment up to 6 h (Fig. 3D).
These results demonstrate that the glycogen levels were rapidly
modulated in response to changes in extracellular glucose level
and that PGM1 is closely involved in cellular glycogen metabolism.
3.4. PGM1 is required for maintenance of cell proliferation during
repetitive glucose depletion
According to previous reports, glycogen appears to be used
when extracellular glucose levels are insufﬁcient to meet theFig. 4. PGM1 is required for cell proliferation under repetitive glucose depletion. (A) Simp
MCF7 and Hela cells stably infected with lentivirus expressing shRNA PGM1 (shPGM1) or
or nutrient stress conditions (periodic glucose depletion as described in Section 2) (D an
least two separate experiments conducted in triplicate. (F–H) Glycogen, G-1-P and G-6-
10 mM glucose refeeding (R) and 2 h after glucose deprivation (D) as denoted in D.energy demand for cell survival and proliferation [14–21]. Given
that PGM1 affects the rate of G-1-P and glycogen turnover, we
hypothesized that PGM1 maintains cell growth under the extracel-
lular nutritional ﬂuctuations by enabling the interconversion of
G-1-P and G-6-P during metabolic adaptation (Fig. 4A).
To examine the consequences of PGM1 depletion we generated
stable PGM1 knockdown MCF7 and Hela cells (Fig. S4). As shown in
Fig. 4B and C, PGM1 knockdown did not affect cell proliferation in
standard culture condition. Since prolonged glucose depletion
induced cell death in both shNC and shPGM1, we developed a pro-
tocol that reﬂects repetitive nutritional stress by exposing cells tole diagram showing utilization of G-1-P and G-6-P in the cellular environment. (B–E)
control shRNA (shNC) were cultured in 24 mM glucose containing medium (B and C)
d E). Cell number was counted at 24-h intervals. The results are representative of at
P contents in MCF7 cells (j: NC and h: shPGM1). Cells were harvested at 2 h after
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of glucose depletion in order to evaluate the role of PGM1 in met-
abolic adaptation against long-term nutritional stress without
occurring cell death (Fig. S5). Cell numbers were counted every
24 h for 4 days.
Notably, shNC cells continued to grow under conditions of
repetitive glucose depletion whereas cells lacking PGM1 showed
severely suppressed growth (Fig. 4D and E). This result could be
expected by the fact that PGM1mediates glycogen storage and gly-
cogen turnover rate as shown in Fig. 3C and D. To evaluate this
hypothesis, glycogen, G-6-P, and G-1-P were measured in shNC
and shPGM1 cells at the indicated time point in Fig. 4D (denoted
by R and D). Addition of 10 mM glucose for 2 h after glucose deple-
tion for 20 h rapidly increased the glycogen, and then following 2 h
of glucose deprivation abruptly decreased glycogen in NC cells.
This dynamic change in glycogen level according to glucose avail-
ability was severely blunted by PGM1 knockdown (Fig. 4F). The lev-
els of G-1-P and G-6-P were also dynamically regulated by glucose
availability and PGM1 knockdown impeded this regulation (Fig. 4G
and H). These data imply that PGM1 is required for sustained pro-
liferation of cells exposed to nutrient stress by regulating glycogen
metabolism.
4. Discussion
PGM1 catalyzes the reversible conversion between G-1-P and
G-6-P. Although G-1-P and G-6-P are important metabolic inter-
mediates of glucose and glycogen metabolism, and glycogen
metabolism in cancer cells was recently focused on recently
[14,18–20], the biological roles and regulatory mechanisms of
PGM1 are largely unknown.
In this study, we present evidence for important roles of C-ter-
minal threonine residues in PGM1 function. Furthermore, we pro-
pose that PGM1 functions as a rheostat of permissive and
detrimental nutritional status by ﬁne-tuning G-1-P turnover with
respect to cell proliferation (Fig. 4A).
We provide several lines of evidence that the C-terminal threo-
nine residues of PGM1 are critical for its stability and activity. We
showed that addition of C-terminal 6His tags to PGM1 totally
compromised enzymatic activity (Fig. 1). C-terminal T533 muta-
tions decreased the expression level in animal cells and led to
misfolded aggregates in E. coli (Fig. 2B and C). Since it is well doc-
umented that mutations that markedly perturb protein folding
trigger rapid hydrolysis [29], we concluded that the T533 residue
is critical for PGM protein into the correct conformation. Deletion
of T562 or T562E mutation completely abolished PGM activity
and the T562A mutant protein required a high concentration of
G-1,6-BP for enzymatic activity (Fig. 2D–G). The reaction catalyzed
by PGM involves sequential formation of a complex of G-1-P and
phosphorylated PGM1, conversion to G-1,6-BP and dephosphoryl-
ated PGM1, and the ﬁnal production of G-6-P and phosphorylated
PGM1. Therefore, it is plausible that formation of a stable complex
between G-1,6-BP and dephosphorylated enzyme is important for
the PGM1 catalytic reaction. If this complex is unstable, dissocia-
tion of G-1,6-BP will result in dephosphorylated PGM1 that has
no catalytic activity by itself. Thus, T562 residue might play a
key role in maintaining a stable complex between G-1,6-BP and
dephosphorylated PGM1.
PGM1 is known to be phosphorylated on serine 108 acting as a
phosphoryl group donor in the production of G-1,6-BP [5], and on
threonine 466 by p21-activated kinase1 (Pak1) contributing to
enhanced activity [13]. Although present study has not elucidated
whether T562 is involved in the regulation of PGM activity in vivo,
the previous reports provide the possibility. PGM1 is known to
interacts with ZASP/Cyper in response to starvation of serum orglucose in cardiac muscle through the last 52 C-terminal residues
of PGM1 including T562, although effects of this interaction on
PGM activity was not determined [30]. In skeletal muscle, PGM1
was reported to be inhibited by interaction with sarcoplasmic
reticulum fraction, of which the blocking by treatment with deter-
gent recovered PGM1 activity, although the precise domain target-
ing to membrane was not determined [31]. These reports provide
the possibility that the interactions of C-terminus of PGM1 with
cytoskeletal proteins or membrane can be the regulatory mecha-
nism as well as the covalent modiﬁcation.
In the present study we demonstrated that PGM1 knockdown
is associated with decreased basal cellular glycogen levels
(Fig. 3B) but not totally depleted probably through the comple-
mentation of PGM isoforms present in the cells. In addition,
shPGM1 showed suppression of glucose depletion-induced glyco-
genolysis and glucose supplementation-induced glycogenesis
(Fig. 3C and D). These results strongly imply that PGM1 is closely
involved in the modulation of glycogen content in response to
extracellular glucose levels. Most studies on cellular glycogen con-
tent have focused on the activities of glycogen synthase [32] and
glycogen phosphorylase [18–20]. Recently, protein phosphatase 1,
regulatory subunit 3C (PPP1R3C) was reported to promote glyco-
gen accumulation under hypoxia [21], and another study showed
that PGM1 expression was increased as a target gene of HIF-1 to
promote the ﬁrst step of glycogenesis in hypoxia [18]. To the best
of our knowledge, our study provides the ﬁrst demonstration that
PGM1 knockdown directly affects glycogen metabolism in cancer
cells.
To delineate the role of PGM1 in cell proliferation under condi-
tions of ﬂuctuating energy stress, we exposed cells to long-term
repetitive nutritional stress by providing intermittent 4-h pulses
of 10 mM glucose between 20-h periods of glucose depletion.
Under these conditions, control cells persistently continued to
grow, whereas PGM1 knockdown cells exhibited marked growth
repression (Fig. 4D and E). This result could be expected by our
observations that PGM1 is required for rapid recovery of glycogen
after glucose depletion (Figs. 3D and 4F) which in turn enable cells
to survive followed by glucose depleted conditions. Taken together,
PGM1 is required for the proliferation of cells that are exposed to
long-term metabolic stress, probably through regulating the ﬂux
of G-1-P and G-6-P in response to cellular demands incurred by
changes in the extracellular energy status.
Several recent studies have shown that glycogen accumulation
is induced for cell survival and proliferation under hypoxia and/or
glucose-depleted conditions [18–21]. Therefore, it appears that
cancer cells store energy in glycogen reservoirs for glycolysis,
nucleic acid and de novo fatty acid synthesis when extracellular
glucose levels are insufﬁcient to meet the energy demands. We
showed a critical role of PGM1 in cell proliferation using an exper-
imental model that reﬂects the dynamic nutritional status of
repetitive glucose depletion that might occur in the tumor micro-
environment (Fig. 4A). Our observation that PGM1 affects glycogen
synthesis and degradation indicates that PGM1 allows cancer cells
to overcome nutrient-depleted conditions by facilitating adequate
use of glycogen. However, we cannot exclude the possibility that
G-1-P is also required for the synthesis of UDP-glucose and UDP-
galactose to produce glycoproteins and glycolipids which are
important for cellular functions [9,14–16]. Therefore, beneﬁcial
effects of galactose supplementation in shPGM1 cells need to be
observed in future studies.
Taken together, our results suggest that PGM1 provides the
ability to sustain cell growth throughout frequent changes in nutri-
tional supply, probably through regulating the balance of G-1-P
and G-6-P in order to satisfy the ﬂuctuating cellular demands
incurred by nutritional stress.
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